GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting
“We are excited to share initial results from these two investigator-sponsored trials of uproleselan regarding safety and preliminary efficacy in frontline unfit and treated secondary AML populations not previously studied with this novel investigational agent,” said
Details on
Publication Number: 1448
Title: Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)
Authors:
Session
Session Date/ Presentation Time:
Location:
Publication Number: 2764
Title: A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia
Authors: Brian A Jonas, Jeanna L Welborn, Naseem S Esteghamat, Rasmus T Hoeg, Aaron S Rosenberg,
Session
Session Date/Presentation Time:
Location:
About Uproleselan
Discovered and developed by
About
Forward-Looking Statements
To the extent that statements contained herein are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of the management of
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005322/en/
Investors:
Leo Vartorella / Carrie McKim
212-600-1902
Glycomimetics@argotpartners.com
Source: